See LIPO-C dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
LIPO-C is a methionine + inositol + choline (MIC) lipotropic injection blend, often extended with B-complex vitamins, used in weight-loss and metabolic clinics for hepatic lipid mobilization. The combined formulation has a long off-label clinic history but no controlled clinical trials of the blend specifically. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select when working with LIPO-C.
LIPO-C is the standard methionine + inositol + choline (MIC) lipotropic injection blend used in weight-loss and metabolic clinic practice for the past several decades, often extended with B-complex vitamins (B12 cyanocobalamin, B6 pyridoxine, B5 pantothenic acid) in the "MIC + B-vitamins" presentation that dominates the modern formulary. The pharmacological rationale rests on the role of the three lipotropic constituents in hepatic methyl-donor metabolism and one-carbon flux: methionine and choline are direct methyl donors required for phosphatidylcholine synthesis and VLDL packaging of triglycerides for export from the liver, while inositol contributes to phosphoinositide signaling and lipid trafficking.
LIPO-C is a compounding-pharmacy lipotropic injection blend — methionine, inositol, choline, and B-vitamins plus added L-carnitine and B12 — most often sourced for fat-loss support research. It is a multi-ingredient mixture, not a single peptide, and usually ships as a pre-mixed sterile solution. See the standalone LIPO-B entry for the regulatory framing and evidence base.
The LIPO-C rationale extends the LIPO-B "lipotropic" framing with L-carnitine, which functions physiologically as the obligatory co-factor for transporting long-chain fatty acids across the inner mitochondrial membrane for β-oxidation. The theoretical claim is that supplemental injectable carnitine boosts fat-oxidation capacity beyond what endogenous carnitine supports, accelerating fat loss. **As with LIPO-B, the combined-product mechanism for weight loss in non-deficient adults is largely extrapolated from individual-nutrient pharmacology rather than demonstrated for the specific LIPO-C formulation in controlled trials.**
No registered controlled trial has evaluated a specific LIPO-C / MICC injection formulation for weight loss. Component-level carnitine research includes the Stephens / Brass body of work on muscle carnitine content and exercise fat-oxidation, which suggests that meaningful changes in muscle carnitine require sustained co-administration with insulin (carbohydrate) rather than bolus injection. FDA-approved L-carnitine (levocarnitine, Carnitor) exists for primary carnitine deficiency but the off-label LIPO-C use is compounding-pharmacy only.
LIPO-C has a reported half-life of varies by component, and the dose intervals researchers model most often fall around weekly. A lipotropic blend (typically MIC plus carnitine) with no single half-life — components clear at different rates, so the weekly injection acts as a periodic top-up rather than building a steady level. It is catalogued under Weight Loss on WPA.
74 LIPO-C reconstitution calculations have been logged by the WPA community. The most common dose entered is 5mg (16 calculations). The median dose across all sessions is 1mg. The most common bacteriostatic water volume is 10mL. The most popular vial size is 10mg (46 sessions). The most common dosing frequency is once weekly (8 logged protocols), followed by 2x/week (4).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.